BioSpace News Archive

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website . In January 2020, Yield10 submitted an “Am I Regula

BOSTON, April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a corporate update and discuss financial results for the first quarter ended March 31, 2020. The call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (international). The passcode for the conference call is 13701877. To access the live webcast or the subsequent archi

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Halley E. Gilbert has been appointed to the Arcutis Board of Directors effective May 1, 2020. “We are thrilled to welcome Halley to the Arcutis Board,” said Frank Watanabe ,

Anika Therapeutics, Inc. today announced that Cheryl R. Blanchard, Ph.D., has been named President and Chief Executive Officer,

PharmaNutra S.p.A. (Aim Italia: PHN), pharmaceutical company leader in the iron-based nutritional supplements market and already present in 50 countries, announces that it has obtained new significant assets, strategic for the Group’s international expansion

COM701 was well-tolerated with no dose-limiting toxicities observed as a monotherapy and in combination with Opdivo® (nivolumab)

$50 Million Series A Financing Led by GV and ARCH Venture Partners with Participation from Partners Innovation Fund

Epizyme, Inc. announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET.

Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen

Data demonstrated superiority of both test arms in co-primary outcome measures of axial length and cycloplegic spherical equivalent refraction (SER) over control lenses at 12-month planned interim analysis